Joynt RJ, ed. Clinical neurology, rev. Philadelphia: JB Lippincott, Chapter 24, 1993.
Hakim J. Epidemiology of HIV CNS disease in sub-Saharan Africa. Second HIV Infection and the Central Nervous System: Developed and Resource-Limited Settings, Venice, Italy, 2007.
Schutte CM The impact of HIV on meningitis as seen at a South African Academic Hospital (1994 to 1998). Infection; 28(1):3-7, 2000.
McCarthy KM et al. Population-based surveillance for cryptococcosis in
an antiretroviral-naive South African province with a high HIV seroprevalence. AIDS, 20:2199–2206, 2006.
Hakim JG et al. Impact of HIV infection on meningitis in Harare, Zimbabwe: a prospective study of 406 predominantly adult patients. AIDS;14(10):1401-7, 2000.
Bogaerts J et al. AIDS-associated cryptococcal meningitis in Rwanda (1983–1992): epidemiologic and diagnostic features. J Infect; 39:32–37, 1999.
Békondi C et al. Primary and opportunistic pathogens associated with meningitis in adults in Bangui, Central African Republic, in relation to human immunodeficiency virus serostatus. Int J Infect Dis. 10(5):387-95, 2006.
Jowi JO East. Clinical and laboratory characteristics of hospitalised patients with neurological manifestations of HIV/AIDS at the Nairobi hospital. Afr Med J;84(2):67-76, 2007.
Matee MI, Matre R. Pathogenic isolates in meningitis patients in Dar Es Salaam, Tanzania. East Afr Med J. 78(9):458-60, 2001
Chariyalertsak et al. A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand. Clin Infect Dis; 34(2):277-84, 2002.
Helbok R et al. Chronic meningitis in Thailand. Clinical characteristics, laboratory data and outcome in patients with specific reference to tuberculosis and cryptococcosis. Neuroepidemiology;26(1):37-44, 2006.
Subsai K et al. Neurological complications in AIDS patients: the 1-year retrospective study in Chiang Mai University, Thailand. Eur J Neurol; 11:755–9, 2004.
Ghate M. Epidemiology of HIV CNS disease in India. Second HIV Infection and the Central Nervous System: Developed and Resource-Limited Settings, Venice, Italy, 2007.
Pallangyo K et al. High HIV seroprevalence and increased HIV-associated mortality among hospitalized patients with deep bacterial infections in Dar es Salaam, Tanzania. AIDS;6(9):971-6, 1992.
Cecchini D Tuberculous meningitis in HIV-infected patients: drug susceptibility and clinical outcome. AIDS;21(3):373-4, 2007.
Thwaites GE et al. The influence of HIV infection on clinical presentation, response to treatment, and outcome in adults with Tuberculous meningitis. J Infect Dis;192(12):2134-41, 2005.
G.E. Thwaites. Central Nervous System Tuberculosis. Second HIV Infection and the Central Nervous System: Developed and Resource-Limited Settings, Venice, Italy, 2007.
M.G. Croda et al. Associated factors to in-hospital mortality and long-term
survival in Brazilian HIV-infected patients with tuberculous meningitis in the HAART era. Second HIV Infection and the Central Nervous System: Developed and Resource-Limited Settings, Venice, Italy, 2007.
Maher D, Mwandumba H. Cryptococcal meningitis in Lilongwe and Blantyre, Malawi. J Infect;28(1):59-64, 1994.
Soumaré M et al. Epidemiological, clinical, etiological features of neuromeningeal diseases at the Fann Hospital Infectious Diseases Clinic, Dakar (Senegal). Med Mal Infect;35(7-8):383-9, 2005.
Mwaba P et al Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions. Postgrad Med J;77(914):769-73, 2001.
Moosa MYS, Coovadia YM. Cryptococcal meningitis in Durban, South Africa: a comparison of clinical features,laboratory findings and outcome for human immunodeficiency virus (HIV)-positive and HIV-negative patients. Clin Infect Dis; 24:131–134, 1997.
Bergemann A, Karstaedt AS. The spectrum of meningitis in a population with high prevalence of HIV disease. QJM;89(7):499-504, 1996.
Scarborough M, Njalale Y. Bacterial meningitis in a high HIV prevalence setting in sub-Saharan Africa--challenges to a better outcome. Trop Doct; 34(4):203-5, 2004.
de Almeida SM et al. Acute bacterial meningitis in HIV, patients in southern Brazil: Curitiba, Paraná, Brazil. Arq Neuropsiquiatr;65(2A):273-8, 2007.
Almirante B et al. Favorable prognosis of purulent meningitis in patients infected with human immunodeficiency virus. Clin Infect Dis;27:176-180, 1998.
Molyneux EM et al. The effect of HIV infection on paediatric bacterial meningitis in Blantyre, Malawi. Arch. Dis. Child.; 88;1112-1118, 2003.
Gordon SB et al. Bacterial meningitis in Malawian adults: pneumococcal disease is common, severe, and seasonal. Clin Infect Dis;31(1):53-7, 2000.
Janoff EN et al. Pneumococcal disease during HIV infection: epidemiologic, clinical, and immunologic perspectives. Ann Intern Med;117:314–24, 1992.
Simon, RP. Neurosyphilis. Arch Neurol;42: 606-613, 1985
Carmo RA et al. Syphilitic meningitis in HIV-patients with meningeal syndrome: report of two cases and review. Braz J Infect Dis;5(5):280-7, 2001.
Johns DR et al Alteration in the natural history of neurosyphilis by concurrent infection with the human immunodeficiency virus. N Engl J Med;316(25):1569-72, 1987.
Padayatchi N et al. Multidrug-resistant tuberculous meningitis in children in Durban, South Africa. Pediatr Infect Dis J;25(2):147-50, 2006.
Wilson D et al (eds). South African Handbook of HIV Medicine. Cape Town, Oxford University Press Southern Africa, Chapter 19, 2002.
Karstaedt AS et al. Tuberculous meningitis in South African urban adults. QJM;91(11):743-7, 1998.
French N et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1 infected Ugandan adults: double-blind, randomised and placebo controlled trial. The Lancet 355: 2106-2111, 2000.
Gluckman SJ. Cryptococcal infections in patients with AIDS. Bostwana International HIV Conference. Gaborone, 2006.
Nowak DA et al. A retrospective clinical, laboratory and outcome analysis in 43 cases of acute aseptic meningitis. Eur J Neurol;10(3):271-80, 2003.
WHO. Laboratory manual for the diagnosis of meningitis caused by Neisseria meningitidis, Streptococcus pneumoniae and Haemophilus influenzae, Geneva, Switzerland, 1997.
van der Horst CM et al. Treatment of cryptococcal meningitis associated with acquired immunodeficiency syndrome. N Engl J Med; 337:15–21, 1997.
Graybill JR et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. Clin Infect Dis; 30: 47–54, 2000.
McCarthy K and Meintjes G, Convenors. Guidelines for the prevention, diagnosis and management of cryptococcal meningitis and disseminated cryptococcosis in HIV-infected patients The Southern African Journal of HIV Medicine, Spring 2008.
CDC (Centers for Disease Control and Prevention). Guidelines for treatment of sexually transmitted diseases. MMWR 47:1-116, 1998.
Brown DL, Frank JE. Diagnosis and management of syphilis. Am Fam Physician;68(2):283-90, 2003.
Sungkanuparph S. Cryptococcosis of the central nervous system: classical and immune-reconstitution disease. Second HIV Infection and the Central Nervous System: Developed and Resource-Limited Settings, Venice, Italy, 2007.
Thwaites GE et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med; 351:1741–51, 2004.
WHO and UNAIDS: Management of sexually transmitted diseases. WHO/GPA/TEM/94/1 Rev 1, Geneva, 1997.
Saag MS et al. Practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2000; 30:710–8.
Brouwer AE, Rajanuwong A, Chierakul W, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomized trial. Lancet; 363:1764–7, 2004.
Lortholary O. Management of cryptococcal meningitis in AIDS: the need for specific studies in developing countries. Clinical Infectious Diseases 2007; 45:81–3.
Schaars CF et al. Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole. BMC Infectious Diseases; 6: 118, 2006.
Bicanic T. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clinical Infectious Diseases; 45:76–80, 2007.
Jongwutiwes, U et al. Impact of antiretroviral therapy on the relapse of cryptococcosis and survival of HIV-infected patients with cryptococcal infection. Current HIV Research, 5(3),355-360(6), 2007.
Sungkanuparph S et al. Opportunistic infections after the initiation of highly active antiretroviral therapy in advanced AIDS patients in an area with a high prevalence of tuberculosis. AIDS. 17(14):2129-2131, September 26, 2003.
Lawn SD et al. Cryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme. AIDS 2005; 19:2050–2.
Pitt J et al. The effect of fluconazole on nevirapine pharmacokinetics. Int Conf AIDS; 15: abstract no. WeOrB1239, 2004.
Manosuthi W et al. Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study. BMC Infectious Diseases 5:67, 2005.
Manosuthi W et al. Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole BMC Infectious Diseases 7:14, 2007.
Mulenga V et al. Effect of cotrimoxazole on causes of death, hospital admissions and antibiotic use in HIV-infected children. AIDS 21: 77-84, 2007.
Chang L et al. Antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV. Cochrane Database Syst Rev (3):CD004773, 2005.
Chetchotisakd P et al. A multicentre, randomized, double-blind, placebo-controlled trial of primary cryptococcal meningitis prophylaxis in HIV-infected patients with severe immune deficiency. HIV Med;5(3):140-3, 2004.